{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:34:58Z","timestamp":1790706898892,"version":"4.1.0"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although several decades have passed since the description of myeloproliferative neoplasms (MPN), many aspects of their pathophysiology have not been elucidated. In this review, we discuss the mutational landscape of patients with essential thrombocythemia (ET), prognostic scores and salient pathology, and clinical points. We discuss also the diagnostic challenges of differentiating ET from prefibrotic MF.<\/jats:p><jats:p>We then focus on post-essential thrombocythemia myelofibrosis (post-ET MF), a rare subset of MPN that is usually studied in conjunction with post-polycythemia vera MF. The transition of ET to post-ET MF is not well studied on a molecular level, and we present available data. Patients with secondary MF could benefit from allogenic hematopoietic stem cell transplantation, and we present available data focusing on post-ET MF.<\/jats:p>","DOI":"10.1093\/labmed\/lmac074","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:53:28Z","timestamp":1660326808000},"page":"13-22","source":"Crossref","is-referenced-by-count":7,"title":["Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar Castaneda","family":"Puglianini","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute, Department of Blood & Marrow Transplant & Cellular Immunotherapy , Tampa, FL , USA"},{"name":"Department of Oncologic Sciences, University of South Florida Morsani College of Medicine , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Peker","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-075X","authenticated-orcid":false,"given":"Linsheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadantonakis","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"2023010801582696600_CIT0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"2023010801582696600_CIT0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"2023010801582696600_CIT0003","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol."},{"key":"2023010801582696600_CIT0004","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med."},{"key":"2023010801582696600_CIT0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12288-017-0913-x","article-title":"Summary and review of the abstracts on Philadelphia-negative myeloproliferative neoplasms presented at Haematocon 2017","volume":"34","author":"Chatterjee","year":"2018","journal-title":"Indian J Hematol Blood Transfus."},{"key":"2023010801582696600_CIT0007","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12885-019-5764-4","article-title":"Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000\u20132018","volume":"19","author":"Mej\u00eda-Ochoa","year":"2019","journal-title":"BMC Cancer."},{"key":"2023010801582696600_CIT0008","first-page":"1","article-title":"CALR-ETdb, the database of calreticulin variants diversity in essential thrombocythemia","volume":"00","author":"El Jahrani","year":"2021","journal-title":"Platelets."},{"key":"2023010801582696600_CIT0009","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia."},{"key":"2023010801582696600_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2019.317","article-title":"Recent insights regarding the molecular basis of myeloproliferative neoplasms","volume":"35","author":"Jang","year":"2020","journal-title":"Korean J Intern Med."},{"key":"2023010801582696600_CIT0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"2023010801582696600_CIT0012","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience","volume":"2","author":"Alduaij","year":"2018","journal-title":"HemaSphere."},{"key":"2023010801582696600_CIT0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14713","article-title":"Advances in understanding the pathogenesis of familial myeloproliferative neoplasms","volume":"178","author":"Rumi","year":"2017","journal-title":"Br J Haematol."},{"key":"2023010801582696600_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071810","article-title":"Aetiology of myeloproliferative neoplasms","volume":"12","author":"McMullin","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2023010801582696600_CIT0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.22212","article-title":"Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson","year":"2012","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0016","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/arpa.2013-0018-OA","article-title":"Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F","volume":"138","author":"Vytrva","year":"2014","journal-title":"Arch Pathol Lab Med."},{"key":"2023010801582696600_CIT0017","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4161\/cc.6325","article-title":"Direct visualization of the endomitotic cell cycle in living megakaryocytes: differential patterns in low and high ploidy cells","volume":"7","author":"Papadantonakis","year":"2008","journal-title":"Cell Cycle."},{"key":"2023010801582696600_CIT0018","first-page":"95","article-title":"Development of megakaryocytes","volume-title":"Molecular Basis of Hematopoiesis","author":"Papadantonakis"},{"key":"2023010801582696600_CIT0019","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-0609.1996.tb00717.x","article-title":"Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis","volume":"56","author":"Jacobsson","year":"2009","journal-title":"Eur J Haematol."},{"key":"2023010801582696600_CIT0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.V74.2.594.594","article-title":"Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts","volume":"74","author":"Tomer","year":"1989","journal-title":"Blood."},{"key":"2023010801582696600_CIT0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur J Haematol."},{"key":"2023010801582696600_CIT0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-009-0411-5","article-title":"Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation","volume":"90","author":"Sever","year":"2009","journal-title":"Int J Hematol."},{"key":"2023010801582696600_CIT0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol."},{"key":"2023010801582696600_CIT0024","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.3324\/haematol.2019.227686","article-title":"Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a \u201cgrey zone\u201d combination of myelodysplastic and myeloproliferative features?","volume":"105","author":"Sangiorgio","year":"2020","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.15562","article-title":"What is pre-fibrotic myelofibrosis and how should it be managed in 2018?","volume":"183","author":"Curto-Garcia","year":"2018","journal-title":"Br J Haematol."},{"key":"2023010801582696600_CIT0026","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"Rumi","year":"2017","journal-title":"Oncotarget."},{"key":"2023010801582696600_CIT0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-017-0006-y","article-title":"Essential thrombocythemia vs. pre-fibrotic\/early primary myelofibrosis: discrimination by laboratory and clinical data","volume":"7","author":"Schalling","year":"2017","journal-title":"Blood Cancer J."},{"key":"2023010801582696600_CIT0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3960\/jslrt.18006","article-title":"Histological evaluation of myeloproliferative neoplasms","volume":"58","author":"Fujiwara","year":"2018","journal-title":"J Clin Exp Hematop."},{"key":"2023010801582696600_CIT0029","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia."},{"key":"2023010801582696600_CIT0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.22241","article-title":"Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia","volume":"87","author":"Carobbio","year":"2012","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jha2.361","article-title":"Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis","volume":"3","author":"Cheng","year":"2022","journal-title":"eJHaem."},{"key":"2023010801582696600_CIT0032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ejh.13236","article-title":"Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan","volume":"102","author":"Edahiro","year":"2019","journal-title":"Eur J Haematol."},{"key":"2023010801582696600_CIT0033","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2169\/internalmedicine.44.1090","article-title":"Iron deficiency anemia with marked thrombocytosis complicated by central retinal vein occlusion","volume":"44","author":"Nagai","year":"2005","journal-title":"Intern Med."},{"key":"2023010801582696600_CIT0034","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.2019002039","article-title":"Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice","volume":"134","author":"Xavier-Ferrucio","year":"2019","journal-title":"Blood."},{"key":"2023010801582696600_CIT0035","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ajh.26189","article-title":"Iron and platelets: a subtle, under-recognized relationship","volume":"96","author":"Brissot","year":"2021","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0036","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.12884","article-title":"Increased expression of HIF2\u03b1 during iron deficiency-associated megakaryocytic differentiation","volume":"13","author":"Jimenez","year":"2015","journal-title":"J Thromb Haemost."},{"key":"2023010801582696600_CIT0037","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/2040620715580068","article-title":"Advances and challenges in the management of essential thrombocythemia","volume":"6","author":"Birgeg\u00e5rd","year":"2015","journal-title":"Ther Adv Hematol."},{"key":"2023010801582696600_CIT0038","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med."},{"key":"2023010801582696600_CIT0039","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer."},{"key":"2023010801582696600_CIT0040","first-page":"45","article-title":"Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms","volume-title":"Managing Myeloproliferative Neoplasms.","author":"Scherber"},{"key":"2023010801582696600_CIT0041","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0042","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-020-00588-z","article-title":"Thrombocytosis and thrombosis: is there really a correlation?","volume":"15","author":"Galvez","year":"2020","journal-title":"Curr Hematol Malig Rep."},{"key":"2023010801582696600_CIT0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/9124821","article-title":"The essential thrombocythemia, thrombotic risk stratification, and cardiovascular risk factors","volume":"2020","author":"Mancuso","year":"2020","journal-title":"Adv Hematol."},{"key":"2023010801582696600_CIT0044","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J."},{"key":"2023010801582696600_CIT0045","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11239-018-1663-9","article-title":"The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis","volume":"46","author":"Rottenstreich","year":"2018","journal-title":"J Thromb Thrombolysis."},{"key":"2023010801582696600_CIT0046","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"2023010801582696600_CIT0047","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0048","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00277-021-04527-7","article-title":"Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms","volume":"100","author":"Choi","year":"2021","journal-title":"Ann Hematol."},{"key":"2023010801582696600_CIT0049","doi-asserted-by":"crossref","first-page":"100713","DOI":"10.1016\/j.blre.2020.100713","article-title":"Prognostic models in the myeloproliferative neoplasms","volume":"42","author":"Grinfeld","year":"2020","journal-title":"Blood Rev."},{"key":"2023010801582696600_CIT0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol."},{"key":"2023010801582696600_CIT0051","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"Arachchillage","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"2023010801582696600_CIT0052","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet."},{"key":"2023010801582696600_CIT0053","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ODRR.S93451","article-title":"Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia","volume":"7","author":"Sarma","year":"2017","journal-title":"Orphan Drugs Res Rev."},{"key":"2023010801582696600_CIT0054","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-014-0226-1","article-title":"Antiplatelet therapy in the management of myeloproliferative neoplasms","volume":"9","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Curr Hematol Malig Rep."},{"key":"2023010801582696600_CIT0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF02685904","article-title":"Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment","volume":"24","author":"Hultdin","year":"2007","journal-title":"Med Oncol."},{"key":"2023010801582696600_CIT0056","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1309\/KL7D03X2YTYE0PBB","article-title":"Clinical significance of cytogenetics in myeloproliferative disorders","volume":"38","author":"Suppiah","year":"2007","journal-title":"Lab Med."},{"key":"2023010801582696600_CIT0057","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/medicina57080813","article-title":"The prognostic role of cytogenetics analysis in Philadelphia negative myeloproliferative neoplasms","volume":"57","author":"Lanzarone","year":"2021","journal-title":"Medicina (Kaunas)."},{"key":"2023010801582696600_CIT0058","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4081\/hr.2019.8281","article-title":"Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: a single center study","volume":"11","author":"Accurso","year":"2019","journal-title":"Hematol Rep."},{"key":"2023010801582696600_CIT0059","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0290-9","article-title":"The new WHO classification for essential thrombocythemia calls for revision of available evidences","volume":"10","author":"Barbui","year":"2020","journal-title":"Blood Cancer J."},{"key":"2023010801582696600_CIT0060","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/cancers12082194","article-title":"Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses","volume":"12","author":"Skov","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2023010801582696600_CIT0061","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00032","article-title":"Genetic alterations in essential thrombocythemia progression to acute myeloid leukemia: a case series and review of the literature","volume":"8","author":"Ayres-Silva","year":"2018","journal-title":"Front Oncol."},{"key":"2023010801582696600_CIT0062","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"2023010801582696600_CIT0063","first-page":"4149","article-title":"ASXL1 mutations in Chinese patients with essential thrombocythemia","volume":"15","author":"Nie","year":"2018","journal-title":"Exp Ther Med."},{"key":"2023010801582696600_CIT0064","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"2023010801582696600_CIT0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"2023010801582696600_CIT0066","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"2023010801582696600_CIT0067","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","article-title":"Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms","volume":"3","author":"Hong","year":"2019","journal-title":"Blood Adv."},{"key":"2023010801582696600_CIT0068","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol."},{"key":"2023010801582696600_CIT0069","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"2023010801582696600_CIT0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol."},{"key":"2023010801582696600_CIT0071","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beha.2014.07.003","article-title":"Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?","volume":"27","author":"Bj\u00f6rkholm","year":"2014","journal-title":"Best Pract Res Clin Haematol."},{"key":"2023010801582696600_CIT0072","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0073","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12185-018-2510-7","article-title":"A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia","volume":"108","author":"Kanakura","year":"2018","journal-title":"Int J Hematol."},{"key":"2023010801582696600_CIT0074","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ejh.13454","article-title":"Anagrelide in essential thrombocythemia (ET): results from 150 patients over 25 years by the \u201cPh1-negative Myeloproliferative Neoplasms Latium Group\u201d","volume":"105","author":"Mazzucconi","year":"2020","journal-title":"Eur J Haematol."},{"key":"2023010801582696600_CIT0075","doi-asserted-by":"crossref","first-page":"24102415","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol."},{"key":"2023010801582696600_CIT0076","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000101709","article-title":"Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic\/myeloproliferative diseases","volume":"74","author":"Orazi","year":"2007","journal-title":"Pathobiology."},{"key":"2023010801582696600_CIT0077","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia."},{"key":"2023010801582696600_CIT0078","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res."},{"key":"2023010801582696600_CIT0079","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol."},{"key":"2023010801582696600_CIT0080","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2017.297","article-title":"Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis","volume":"32","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Leukemia."},{"key":"2023010801582696600_CIT0081","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10428194.2018.1522437","article-title":"Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis","volume":"60","author":"Wanquet","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"2023010801582696600_CIT0082","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0083","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","article-title":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib: new perspective of the MYSEC-PM in a large multicenter study","volume":"55","author":"Palandri","year":"2018","journal-title":"Semin Hematol."},{"key":"2023010801582696600_CIT0084","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer."},{"key":"2023010801582696600_CIT0085","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol."},{"key":"2023010801582696600_CIT0086","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/modpathol.3800480","article-title":"Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders","volume":"18","author":"O\u2019Malley","year":"2005","journal-title":"Mod Pathol."},{"key":"2023010801582696600_CIT0087","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/modpathol.2012.33","article-title":"Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition","volume":"25","author":"Prakash","year":"2012","journal-title":"Mod Pathol."},{"key":"2023010801582696600_CIT0088","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol."},{"key":"2023010801582696600_CIT0089","doi-asserted-by":"crossref","first-page":"e8856","DOI":"10.1097\/MD.0000000000008856","article-title":"Abdominal surgery in patients with essential thrombocythemia","volume":"96","author":"Zhu","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"2023010801582696600_CIT0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2017.03.008","article-title":"The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review","volume":"58","author":"Boddu","year":"2017","journal-title":"Leuk Res."},{"key":"2023010801582696600_CIT0091","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"key":"2023010801582696600_CIT0092","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00277-020-04028-z","article-title":"Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol."},{"key":"2023010801582696600_CIT0093","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00277-019-03727-6","article-title":"Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis","volume":"98","author":"Breccia","year":"2019","journal-title":"Ann Hematol."},{"key":"2023010801582696600_CIT0094","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"2023010801582696600_CIT0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071954","article-title":"Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2023010801582696600_CIT0096","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer."},{"key":"2023010801582696600_CIT0097","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"2023010801582696600_CIT0098","first-page":"879","article-title":"Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol Histopathol."},{"key":"2023010801582696600_CIT0099","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv."},{"key":"2023010801582696600_CIT0100","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0101","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica."},{"key":"2023010801582696600_CIT0102","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.bbmt.2012.03.009","article-title":"Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia","volume":"18","author":"Ballen","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"2023010801582696600_CIT0103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"2023010801582696600_CIT0104","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbmt.2017.10.037","article-title":"Transplant decisions in patients with myelofibrosis: should mutations be the judge?","volume":"24","author":"Salit","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"2023010801582696600_CIT0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-018-3240-x","article-title":"Prognostic risk models for transplant decision-making in myelofibrosis","volume":"97","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Ann Hematol."},{"key":"2023010801582696600_CIT0106","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of dynamic international prognostic scoring system and MYelofibrosis SECondary to PV and ET prognostic model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2023010801582696600_CIT0107","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood."},{"key":"2023010801582696600_CIT0108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"2023010801582696600_CIT0109","doi-asserted-by":"crossref","first-page":"204062072090600","DOI":"10.1177\/2040620720906002","article-title":"Allogeneic hematopoietic stem-cell transplantation for myelofibrosis","volume":"11","author":"Zhang","year":"2020","journal-title":"Ther Adv Hematol."},{"key":"2023010801582696600_CIT0110","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"2023010801582696600_CIT0111","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood.V122.21.306.306","article-title":"Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by GOELAMS-FIM in collaboration with the SFGMTC","volume":"122","author":"Robin","year":"2013","journal-title":"Blood."},{"key":"2023010801582696600_CIT0112","article-title":"Peritransplant ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","author":"Ali","year":"2021","journal-title":"Blood Adv."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/1\/13\/48421717\/lmac074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/1\/13\/48421717\/lmac074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T17:30:51Z","timestamp":1700933451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/54\/1\/13\/6663871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmac074","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,8,12]]}}}